Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans
Sign Up to like & getrecommendations! Published in 2019 at "Xenobiotica"
DOI: 10.1080/00498254.2019.1654634
Abstract: Abstract Bexagliflozin is a C-aryl glucoside inhibitor of human sodium-glucose linked transporter 2 (SGLT2) that undergoes oxidation and glucuronidation to form six principal metabolites in humans. In vitro metabolism by human liver microsomes and recombinant… read more here.
Keywords: monkeys humans; inhibitor; metabolism; bexagliflozin ... See more keywords
Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Diabetes"
DOI: 10.1111/1753-0407.13526
Abstract: Bexagliflozin and dapagliflozin are sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. No direct comparison of SGLT2 inhibitors in a randomized controlled trial has been reported to date. read more here.
Keywords: trial; compared dapagliflozin; safety bexagliflozin; bexagliflozin compared ... See more keywords
Safety and effectiveness of the sodium‐glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Veterinary Internal Medicine"
DOI: 10.1111/jvim.16730
Abstract: Abstract Background Bexagliflozin is a sodium‐glucose cotransporter 2 (SGLT2) inhibitor. A pilot study has shown that bexagliflozin can decrease dependence on exogenous insulin in cats with diabetes mellitus (DM). Objective To evaluate the safety and… read more here.
Keywords: safety; safety effectiveness; glucose cotransporter; diabetes mellitus ... See more keywords